摘要
目的观察前列地尔脂微球载体对肾功能中度下降经皮冠状动脉介入治疗的肾脏保护疗效。方法 2018年1月-2019年1月收治的60例肾功能中度下降行经皮冠状动脉介入(PCI)治疗患者为研究对象,按照是否应用前列地尔脂微球载体将所有患者分为对照组(30例:未应用前列地尔脂微球载体)与实验组(30例:应用前列地尔脂微球载体),比较两组患者预后。结果实验组患者术后24 h、48 h Scr、BUN等相关肾功能数值均优于对照组(P<0.05)。实验组患者术后24 h、48 h后LVEF、BNP等相关数值均优于对照组(P<0.05)。实验组患者术后不良反应发生率(0.00%)明显低于对照组(P<0.05)。结论肾功能中度下降行PCI治疗患者应用前列地尔脂微球载体治疗效果明显优于未应用前列地尔脂微球载体而行水化治疗患者疗效。
Objective To observe the renal protective effect of alprostadil liposphere carrier on moderately impaired renal function after percutaneous coronary intervention. Methods From January 2018 to January 2019, 60 patients with moderate decline of renal function were treated with PCI. All patients were divided into control group and experimental group according to whether alprostadil lipid microspheres were used or not. In the control group, 30 patients were not treated with alprostadil lipid microspheres. In the experimental group, 30 patients were treated with alprostadil lipid microsphere carrier. The prognosis of the two groups was compared. Results Scr, BUN and other related renal function values of experimental group were better than those of control group at 24 h, 48 h after operation(P<0.05). The values of LVEF and BNP in experimental group were better than those in control group 24 and 48 hours after operation(P<0.05). The incidence of adverse reactions in the experimental group(0.00%) was significantly lower than that in the control group(P<0.05). Conclusions The effect of alprostadil lipid microsphere carrier in patients with moderate renal dysfunction treated by PCI is better than that of patients treated by hydration without alprostadil lipid microsphere carrier.
作者
吕红江
王静静
韩迎迎
LU Hongjiang;WANG Jingjing;HAN Yingying(Department of Nephrology,the Sixth People's Hospital of Anyang,Henan Province,455000)
出处
《航空航天医学杂志》
2021年第7期774-776,共3页
Journal of Aerospace medicine
关键词
前列地尔脂微球载体
肾功能中度下降
PCI
肾脏保护
Alprostadil lipid microsphere carrier
Moderate decline in renal function
PCI
Kidney protection
